{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:56:32Z","timestamp":1790610992517,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.gastrohep.2025.502379","type":"journal-article","created":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T17:03:57Z","timestamp":1739639037000},"page":"502379","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Alta persistencia al a\u00f1o de vedolizumab v\u00eda subcut\u00e1nea a dosis est\u00e1ndar tras el cambio de vedolizumab intravenoso, incluso en los pacientes intensificados: resultados de un estudio observacional multic\u00e9ntrico espa\u00f1ol"],"prefix":"10.1016","volume":"48","author":[{"given":"Laura","family":"Andr\u00e9s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Iborra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Vicente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Arias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Nos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Royo-Esteban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4495-9358","authenticated-orcid":false,"given":"Beatriz","family":"Sicilia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastrohep.2025.502379_bib0150","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Fegan","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2025.502379_bib0155","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2025.502379_bib0160","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1053\/j.gastro.2019.08.027","article-title":"Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2025.502379_bib0165","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/ecco-jcc\/jjab133","article-title":"Efficacy and safety of subcutaneous vedolizumab in patients with moderately to severely active Crohn's Disease: Results from the VISIBLE 2 randomised trial","volume":"16","author":"Vermiere","year":"2022","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastrohep.2025.502379_bib0170","unstructured":"European Medicines Agency Entyvio. Entyvio (Vedolizumab) An overview of Entyvio and Why It Is Authorised in the EU [consultado 1 Jun 2023] Disponible en: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/entyvio-epar-summary-public_en.pdf"},{"key":"10.1016\/j.gastrohep.2025.502379_bib0175","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/ibd\/izac119","article-title":"Comparative Acceptability of Therapeutic Maintenance Regimens in Patients with Inflammatory Bowel Disease: Results from the Nationwide ACCEPT2 Study","volume":"29","author":"Buisson","year":"2023","journal-title":"Inflamm. Bowel Dis"},{"key":"10.1016\/j.gastrohep.2025.502379_bib0180","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12919-021-00230-7","article-title":"Intravenous versus subcutaneous delivery of biotherapeutics in IBD: An expert's and patient's perspective","volume":"15","author":"Jonaitis","year":"2021","journal-title":"BMC Proc"},{"key":"10.1016\/j.gastrohep.2025.502379_bib0185","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1111\/apt.16927","article-title":"Real-world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease","volume":"55","author":"Bergqvist","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2025.502379_bib0190","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1007\/s10620-024-08422-9","article-title":"Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease","volume":"69","author":"Lamichhane","year":"2024","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.gastrohep.2025.502379_bib0195","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1093\/ecco-jcc\/jjab224","article-title":"Transitioning from Intravenous to Subcutaneous Vedolizumab in Patients with Inflammatory Bowel Disease [TRAVELESS]","volume":"16","author":"Ventress","year":"2022","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastrohep.2025.502379_bib0200","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3390\/ph16020239","article-title":"Real-World Study on Vedolizumab Serum Concentration, Efficacy, and Safety after the Transition from Intravenous to Subcutaneous Vedolizumab in Inflammatory. Bowel Disease Patients: Single-Center Experience","volume":"16","author":"Or\u0161i\u0107 Fri\u010d","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.gastrohep.2025.502379_bib0205","doi-asserted-by":"crossref","first-page":"452","DOI":"10.15403\/jgld-5084","article-title":"Effectiveness and Safety of Switching from Intravenous to Subcutaneous Vedolizumab Formulation in Inflammatory Bowel Disease Patients in Clinical Remission","volume":"32","author":"Parisio","year":"2023","journal-title":"J Gastrointestin Liver Dis"},{"key":"10.1016\/j.gastrohep.2025.502379_bib0210","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.dld.2023.07.011","article-title":"Switching from Vedolizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: The SVEDO Study, an IG-IBD study","volume":"56","author":"Ribaldone","year":"2024","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.gastrohep.2025.502379_bib0215","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/apt.17153","article-title":"Real-world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases","volume":"56","author":"Volkers","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2025.502379_bib0220","doi-asserted-by":"crossref","first-page":"7657","DOI":"10.3390\/jcm12247657","article-title":"Switching Vedolizumab from IV to SC Injection in Inflammatory Bowel Disease Patients with Active Disease: Real-World Experience from a German IBD Cohort","volume":"12","author":"Kubesch","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.gastrohep.2025.502379_bib0225","doi-asserted-by":"crossref","first-page":"otae013","DOI":"10.1093\/crocol\/otae013","article-title":"Subcutaneous Vedolizumab Treatment in a Real-World Inflammatory Bowel Disease Cohort Switched from Intravenous Vedolizumab: Eighteen-Month Prospective Follow-up Study","volume":"6","author":"Wiken","year":"2024","journal-title":"Crohns Colitis 360"},{"key":"10.1016\/j.gastrohep.2025.502379_bib0230","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1080\/00365521.2023.2176252","article-title":"Medhus (2023) Switching from intravenous to subcutaneous vedolizumab maintenance treatment in patients with inflammatory bowel disease followed by therapeutic drug monitoring","volume":"58","author":"Wiken","year":"2023","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502379_bib0235","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3390\/medicina60020296","article-title":"Remission Is Maintained after Switch from Dose-Optimised Intravenous Treatment to Subcutaneous Treatment with Vedolizumab in Inflammatory Bowel Disease","volume":"60","author":"Pintar","year":"2024","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.gastrohep.2025.502379_bib0240","article-title":"Evaluation of the transition from intravenous to subcutaneous vedolizumab in patients with inflammatory bowel disease","author":"Amor Costa","year":"2024","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502379_bib0245","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1093\/ibd\/izad166","article-title":"Safety, effectiveness, and treatment persistence of subcutaneous vedolizumab in IBD: A multicenter study from the United Kingdom","volume":"30","author":"Lim","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastrohep.2025.502379_bib0250","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1080\/00365521.2023.2285229","article-title":"Switching from intravenous to subcutaneous infliximab and vedolizumab in patients with inflammatory bowel disease: Impact on trough levels, day hospital visits, and medical expenses","volume":"59","author":"Harno -Tasihin","year":"2024","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502379_bib0255","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1097\/MEG.0000000000002816","article-title":"Real-life experiences of switching from intravenous to subcutaneous vedolizumab maintenance therapy in patients with inflammatory bowel disease","volume":"36","author":"Kolehmainen","year":"2024","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502379_bib0260","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/gut.2005.082909","article-title":"The Montreal classification of inflammatory bowel disease: Controversies, consensus, and implications","volume":"55","author":"Satsangi","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2025.502379_bib0265","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/ibd.20520","article-title":"Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis","volume":"14","author":"Lewis","year":"2008","journal-title":"Inflamm. Bowel Dis"},{"key":"10.1016\/j.gastrohep.2025.502379_bib0270","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","article-title":"A simple index of Crohn's disease activity","volume":"1","author":"Harvey","year":"1980","journal-title":"Lancet"},{"key":"10.1016\/j.gastrohep.2025.502379_bib0275","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2025.502379_bib0280","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.3390\/jcm10061242","article-title":"Update on TDM (therapeutic drug monitoring) with ustekinumab, vedolizumab and tofacitinib in inflammatory bowel disease","volume":"10","author":"Restellini","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.gastrohep.2025.502379_bib0285","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-019-1323-8","article-title":"Vedolizumab trough level monitoring in inflammatory bowel disease: A state-of-the-art over-view","volume":"17","author":"Pouillon","year":"2019","journal-title":"BMC Med"},{"key":"10.1016\/j.gastrohep.2025.502379_bib0290","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1016\/j.cgh.2023.01.004","article-title":"Therapeutic Drug Monitoring Can Guide the Intravenous-to-Subcutaneous Switch of Infliximab and Vedolizumab: A Simulation Study","volume":"21","author":"Wang","year":"2023","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570525000445?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570525000445?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T12:37:10Z","timestamp":1752583030000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0210570525000445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0210570525000445"],"URL":"https:\/\/doi.org\/10.1016\/j.gastrohep.2025.502379","relation":{},"ISSN":["0210-5705"],"issn-type":[{"value":"0210-5705","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alta persistencia al a\u00f1o de vedolizumab v\u00eda subcut\u00e1nea a dosis est\u00e1ndar tras el cambio de vedolizumab intravenoso, incluso en los pacientes intensificados: resultados de un estudio observacional multic\u00e9ntrico espa\u00f1ol","name":"articletitle","label":"Article Title"},{"value":"Gastroenterolog\u00eda y Hepatolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastrohep.2025.502379","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"502379"}}